"mutated brca12 genes" trang 2 - tải miễn phí từ tailieunhanh
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated nonsmall-cell lung cancer

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated nonsmall-cell lung cancer
8    56    0
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
10    43    0
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study
10    63    0
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
11    45    1
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: An observational study

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: An observational study
10    51    1
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    87    1
Succinate dehydrogenase deficiency in a PDGFRA mutated GIST

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
11    74    1
Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose

Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose
14    50    1
Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia

Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia
12    32    1
Association between ATM rs1801516 polymorphism and cancer susceptibility: A meta-analysis involving 12,879 cases and 18,054 controls

Association between ATM rs1801516 polymorphism and cancer susceptibility: A meta-analysis involving 12,879 cases and 18,054 controls
15    23    1
NRASQ61K mutated primary leptomeningeal melanoma in a child: Case presentation and discussion on clinical and diagnostic implications

NRASQ61K mutated primary leptomeningeal melanoma in a child: Case presentation and discussion on clinical and diagnostic implications
6    52    1
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib
10    75    1
ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
8    67    1
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer
9    45    1
Efficacy of sorafenib in BRAF-mutated nonsmall-cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report

Efficacy of sorafenib in BRAF-mutated nonsmall-cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report
5    72    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/ bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/ bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
10    50    1
Frequency and distribution of Notch mutations in tumor cell lines

Frequency and distribution of Notch mutations in tumor cell lines
11    55    1
SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation
13    64    1
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
3    40    1